← Browse by Condition
Medical Condition

excessive sleepiness

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT06568367 Phase 3
Recruiting

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Enrollment
520 pts
Location
United States, Canad...
Sponsor
Axsome Therapeutics, Inc.
View Trial →